- Spirovant

Leading the Revolution in Treating Genetic Lung Diseases

Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases. We are the only company advancing programs with both AAV and lentivirus vectors.

Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer

13 May , 2020   Press Releases

Spirovant Sciences today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in respiratory sciences and drug discovery with 20+ years of research and executive leadership experience, most recently at MedImmune, AstraZeneca’s global biologics organization.

Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance

30 Dec , 2019   News

Effective December 27, 2019, DSP has acquired from Roivant 100% of “Sumitovant Biopharma,” a newly formed company, and Roivant’s ownership interest in the five subsidiary companies, including Spirovant, that comprise Sumitovant.

How a small Philadelphia gene therapy company became part of a $3B deal

13 Nov , 2019   News

The article in the Philadelphia Business Journal features how Spirovant is developing two gene therapies to treat, and potentially cure, cystic fibrosis.